gutflix
GI learning, personalised

Summary

REAL-WORLD DATA ON THE TREATMENT WITH MIRIKIZUMAB IN A MOSTLY BIOLOGICAL-EXPERIENCED ULCERATIVE COLITIS COHORT

Karima Farrag

UEG Week Vienna 2024 | Poster

IBD

October 13, 2024

Retrospective real-world analysis of 21 ulcerative colitis patients treated with mirikizumab at a single center shows reduction in clinical and biochemical disease activity at 12 weeks, primarily in biological-experienced patients.

KEY POINTS

- Among 21 ulcerative colitis patients, 18 had received at least one prior biological agent, 13 had received 2 or more, and 6 had received 4 or more biological agents before starting mirikizumab.
- Median Simple Clinical Colitis Activity Index decreased from 7 at baseline to 2 at week 12, and median fecal calprotectin decreased from 642 at baseline to 253 at week 12.
- Eleven patients required extended intravenous induction therapy, four patients were re-induced after prior subcutaneous mirikizumab, and one patient discontinued due to primary non-response.
- One patient reported new nodulous skin lesions after treatment; the authors characterize mirikizumab as effective and safe in this heavily pre-treated population.
- This preliminary single-center retrospective study addresses a gap in real-world evidence for mirikizumab in biological-experienced ulcerative colitis patients.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/07c1675e-9112-11ef-add9-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.